Article Versions Notes

Zhang Y, Kumar P, Adashek JJ, Skelton WP IV, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Cells. 2022; 11(16):2505. https://doi.org/10.3390/cells11162505

Zhang, Yumeng, Premsai Kumar, Jacob J. Adashek, William P. Skelton, IV, Jiannong Li, Aram Vosoughi, Jad Chahoud, Brandon J. Manley, and Philippe E. Spiess. 2022. "Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma" Cells 11, no. 16: 2505. https://doi.org/10.3390/cells11162505

Zhang, Y., Kumar, P., Adashek, J. J., Skelton, W. P., IV, Li, J., Vosoughi, A., Chahoud, J., Manley, B. J., & Spiess, P. E. (2022). Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Cells, 11(16), 2505. https://doi.org/10.3390/cells11162505